New Pink Sheet PRIME Tracker Reveals The Companies With The Most Entries On EMA Scheme

Securing a place on the European Medicines Agency’s priority medicines scheme is not easy, but some companies have managed to make the grade more than once.

Developers of PRIME-designated drugs are offered enhanced support to help optimize their development plans • Source: Shutterstock

A total of 120 products have been accepted onto the European Medicines Agency's PRIME (priority medicines) scheme since it was launched in 2016, with Janssen leading the pack when it comes to the companies with the most entries in the scheme.

Six products from Janssen have been granted PRIME designation, although one of them has since been withdrawn from the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Europe

More from Geography

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By 

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.